47 results
424B5
CPRX
Catalyst Pharmaceuticals Inc
5 Jan 24
Prospectus supplement for primary offering
5:15pm
include the uncertainty of:
The impact of the COVID-19 pandemic, or any future pandemic, on our business or on the economy generally;
Whether we … and FYCOMPA® are highly uncertain. Factors that will affect our success include the uncertainty of:
The impact of the COVID-19 pandemic, or any future
424B5
CPRX
Catalyst Pharmaceuticals Inc
4 Jan 24
Prospectus supplement for primary offering
6:24pm
uncertain. Factors that will affect our success include the uncertainty of:
The impact of the COVID-19 pandemic, or any future pandemic, on our … and FYCOMPA® are highly uncertain. Factors that will affect our success include the uncertainty of:
The impact of the COVID-19 pandemic, or any future
S-3ASR
CPRX
Catalyst Pharmaceuticals Inc
8 Sep 23
Automatic shelf registration
4:31pm
of:
The impact of the COVID-19 pandemic, or any future pandemic, on our business or on the economy generally;
Whether we will be able to continue
8-K
EX-2.1
yegj6y0v
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.2
1y6ff8r
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-99.1
hvrifjjn7yu
9 Nov 22
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
4:32pm
8-K
EX-10.2
i12akml
12 Jul 22
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus
8:30am
8-K
EX-99.1
1yh6r0
10 May 22
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
4:31pm
8-K
EX-99.1
sarl8qh6hqso5n2qpcm
16 Mar 22
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:53pm
8-K
EX-99.1
uff58zyxuj4zm0
7 Feb 22
2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth
4:49pm
8-K
EX-99.1
pasiuc0razc3 irzcw
9 Nov 21
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
5:29pm